Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Renal Cell 12Parkinson Disease 4, Autosomal Dominant Lewy Body 4von Hippel-Lindau Disease 2Pheochromocytoma 1Paraganglioma 1Kidney Neoplasms 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 30Paclitaxel 12Carboplatin 10Cisplatin 8lenvatinib 7Pemetrexed 5belzutifan 4Oxaliplatin 4Gemcitabine 4Fluorouracil 4Capecitabine 4patritumab deruxtecan 3olaparib 3Leucovorin 3Albumin-Bound Paclitaxel 3Acetaminophen 3Levoleucovorin 2Irinotecan 2Histamine H2 Antagonists 2Histamine Antagonists 2Etoposide 2Docetaxel 2Dexamethasone 2Cetuximab 2Bevacizumab 2130-nm albumin-bound paclitaxel 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × belzutifan × 30 days × Clear all
NCT04626479 2026-05-18

MK-3475-03A

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
400 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05239728 2026-05-15

MK-6482-022

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
1,800 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04626518 2026-05-06

KEYMAKER-U03

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
370 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04736706 2026-05-06

MK-6482-012

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
1,653 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡